Adaptive Biotechnologies Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Bio-Techne's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and Bio-Techne, as reported by MarketBeat.com.

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Bio-Techne has a consensus target price of $396.1111, suggesting a potential downside of 3.12%. Given Adaptive Biotechnologies' higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than Bio-Techne.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Earnings & Valuation

This table compares Adaptive Biotechnologies and Bio-Techne's gross revenue, earnings per share (EPS) and valuation.

Bio-Techne has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bio-Techne beats Adaptive Biotechnologies on 11 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and argenx's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and argenx, as reported by MarketBeat.com.

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. argenx has a consensus target price of $297.8750, suggesting a potential upside of 15.36%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than argenx.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, argenx has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Earnings & Valuation

This table compares Adaptive Biotechnologies and argenx's gross revenue, earnings per share (EPS) and valuation.

Adaptive Biotechnologies has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 54.2% of argenx shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Adaptive Biotechnologies beats argenx on 8 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and QIAGEN's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and QIAGEN, as reported by MarketBeat.com.

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. QIAGEN has a consensus target price of $60.76, suggesting a potential upside of 31.29%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than QIAGEN.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Earnings & Valuation

This table compares Adaptive Biotechnologies and QIAGEN's gross revenue, earnings per share (EPS) and valuation.

QIAGEN has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

QIAGEN beats Adaptive Biotechnologies on 9 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Novavax's net margins, return on equity and return on assets.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 49.9% of Novavax shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.3% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and Novavax, as reported by MarketBeat.com.

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Novavax has a consensus target price of $190.9286, suggesting a potential upside of 49.37%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than Novavax.

Earnings & Valuation

This table compares Adaptive Biotechnologies and Novavax's gross revenue, earnings per share (EPS) and valuation.

Adaptive Biotechnologies has higher revenue and earnings than Novavax. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptive Biotechnologies beats Novavax on 10 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Repligen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Adaptive Biotechnologies has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adaptive Biotechnologies and Repligen, as reported by MarketBeat.

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 29.81%. Given Adaptive Biotechnologies' higher probable upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Repligen.

Earnings and Valuation

This table compares Adaptive Biotechnologies and Repligen's gross revenue, earnings per share (EPS) and valuation.

Repligen has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen beats Adaptive Biotechnologies on 11 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Neurocrine Biosciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Adaptive Biotechnologies has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adaptive Biotechnologies and Neurocrine Biosciences, as reported by MarketBeat.

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Neurocrine Biosciences has a consensus target price of $127.8333, suggesting a potential upside of 38.72%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Neurocrine Biosciences.

Earnings and Valuation

This table compares Adaptive Biotechnologies and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Neurocrine Biosciences has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Neurocrine Biosciences beats Adaptive Biotechnologies on 10 of the 14 factors compared between the two stocks.